430 related articles for article (PubMed ID: 26320063)
1. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
3. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.
Sznol M
Cancer J; 2014; 20(4):290-5. PubMed ID: 25098290
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
6. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
8. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT
Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
[TBL] [Abstract][Full Text] [Related]
9. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
12. Prospects for targeting PD-1 and PD-L1 in various tumor types.
Kim JW; Eder JP
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
14. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
Gettinger S; Herbst RS
Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
Karim S; Leighl N
Future Oncol; 2016 Jan; 12(1):9-23. PubMed ID: 26631501
[TBL] [Abstract][Full Text] [Related]
16. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
17. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
He J; Hu Y; Hu M; Li B
Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive markers for the new immunotherapies.
Mahoney KM; Atkins MB
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
[TBL] [Abstract][Full Text] [Related]
19. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Chen DS; Irving BA; Hodi FS
Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
